Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults

NCT07463378 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 26-0193
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1 research study evaluating the safety and potential benefits of a topical gel called LUT017 in helping skin wounds heal after minor skin procedures. The study will enroll healthy adults who are already scheduled to have two benign (non-cancerous) skin lesions, such as moles, removed as part of routine care. When the lesions are removed, two small wounds will be created. One wound will be treated with LUT017 gel, and the other will be treated with a placebo gel that does not contain active medication. This allows each participant to serve as their own comparison. The study team will monitor how the wounds heal over approximately one week using clinical evaluation, photographs, and safety assessments. LUT017 is a topical medication designed to activate natural skin repair pathways and potentially promote faster healing. The main purpose of this study is to determine whether a single application of LUT017 gel is safe and well tolerated when applied to fresh skin wounds, and to look for early signs that it may improve or speed up wound healing compared to placebo. The primary question this study aims to answer is: Is LUT017 gel safe when applied to acute skin wounds, and does it show preliminary evidence of improving early wound healing in healthy adults? Participants will be followed for about one week after treatment, with blood tests and skin evaluations to monitor for any side effects. The information gathered from this study will help determine whether LUT017 should continue to be developed as a potential treatment to support wound healing.

Conditions

Wound Healing; Acute Skin Wounds

Keywords

LUT017; Topical BRAF Inhibitor; BRAF Inhibition; Paradoxical MAPK Activation; MAPK Pathway; Wound Healing; Acute Cutaneous Wounds; Skin Wound Repair; Re-epithelialization; Excisional Wound Model; Benign Skin Lesion Removal; Dermatologic Surgery; Phase 1 Clinical Trial; Topical Drug Administration; Pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events (TEAEs)

  Safety and tolerability of a single topical application of LUT017 gel assessed by the number and severity of treatment-emergent adverse events, including local cutaneous reactions, systemic adverse events, clinically significant laboratory abnormalities, and investigator-assessed relatedness to study drug.

  From Day 0 (study drug administration) through Day 7 follow-up visit (±2 days)

Secondary Outcomes (3)

• Investigator-Assessed Early Wound Healing Progression

  Day 7 (±2 days) after study drug administration

• Standardized Photographic Documentation of Wound Healing

  Day 7 (±2 days) after study drug administration

• Investigator Determination of LUT017 Re-application

  Day 7 (±2 days) after study drug administration

Study Arms (3)

UT017 Gel 0.03%

EXPERIMENTAL

Subjects receive a single topical application of LUT017 gel 0.03% to one acute excisional wound and placebo gel to a paired wound immediately following benign lesion removal. Safety, tolerability, pharmacokinetics, and early wound healing are assessed over 7 days.

Drug: LUT017,Topical BRAF inhibitor

LUT017 Gel 0.1%

EXPERIMENTAL

Subjects receive a single topical application of LUT017 gel 0.1% to one acute excisional wound and placebo gel to a paired wound immediately following benign lesion removal. Safety, tolerability, pharmacokinetics, and early wound healing are assessed over 7 days.

Drug: LUT017,Topical BRAF inhibitor

LUT017 Gel 0.25%

EXPERIMENTAL

Subjects receive a single topical application of LUT017 gel 0.25% to one acute excisional wound and placebo gel to a paired wound immediately following benign lesion removal. Safety, tolerability, pharmacokinetics, and early wound healing are assessed over 7 days.

Drug: LUT017,Topical BRAF inhibitor

Interventions

LUT017,Topical BRAF inhibitor DRUG

LUT017 gel is a topical formulation of a small-molecule BRAF inhibitor developed to induce paradoxical activation of the MAPK pathway in BRAF wild-type keratinocytes. The gel is administered once directly to the open wound. Three concentrations (0.03%, 0.1%, and 0.25% w/w) and placebo are evaluated sequentially using a 3+3 dose-escalation design. The formulation is an aqueous-based gel containing organic solvents to optimize dermal penetration while minimizing systemic absorption. Treatment is applied in clinic by qualified investigators.

LUT017 Gel 0.1%; LUT017 Gel 0.25%; UT017 Gel 0.03%

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects scheduled to undergo excision of two or more clinically benign skin lesions (e.g., melanocytic nevi or seborrheic keratoses) that will result in at least two comparable acute cutaneous wounds suitable for study treatment.
• Subject must be ≥ 18 years of age.
• Subjects must be in generally good health, with no dermatologic or systemic condition that may impair normal wound healing, as determined by the Investigator.
• Lesions selected for excision must be benign, confirmed clinically by the treating dermatologist or surgeon prior to the procedure.
• Must be able and willing to provide informed consent prior to study participation.
• Female subjects of childbearing potential must have a negative pregnancy test at day 0. They should agree to use highly effective methods of birth control, defined as those with failure less than 1%, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUD's), sexual abstinence, or a vasectomized partner.

You may not qualify if:

• Any lesion scheduled for excision that is suspicious for malignancy or has not been clinically assessed as benign by the treating dermatologist or surgeon.
• History of abnormal wound healing, including keloid formation, hypertrophic scarring, chronic non-healing wounds, or delayed healing after prior procedures.
• Target ulcer shows any signs of infection (only non-infected ulcers are eligible).
• Unable to tolerate multi-layer bandages or compression garments.
• Decompensated congestive heart failure.
• Active soft tissue or bone infection requiring antibiotics.
• Skin cancer on the target limb within the last 24 months.
• Actively receiving chemotherapy and/or radiation therapy for cancer.
• Treatment with a serine/threonine-protein kinase BRAF inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), BraftoviTM (encorafenib) or Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Day 0, whichever is longer.
• Blood chemistry and complete blood count (CBC) values from the most recent laboratory assessment performed within the past 12 monsth:
• White Blood Cells (WBC) \< 1.5 x 109/L.
• Absolute \< 0.9 x 109/L.
• Platelet count \< 50 x 109/L.
• Alanine aminotransferase \> 3 x upper limit of normal.
• Aspartate aminotransferase \> 3 x upper limit of normal.

Sponsors & Collaborators

• Antoni Ribas: lead

Study Sites (1)

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

Related Publications (17)

• Zhu S, Li S, Escuin-Ordinas H, Dimatteo R, Xi W, Ribas A, Segura T. Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. J Control Release. 2018 Jul 28;282:156-165. doi: 10.1016/j.jconrel.2018.05.006. Epub 2018 May 9.

  PMID: 29751029 BACKGROUND

• Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther. 2005 Apr;4(4):650-8. doi: 10.1158/1535-7163.MCT-04-0238.

  PMID: 15827339 BACKGROUND

• Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, Vonderfecht S. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat. Toxicol Pathol. 2011 Aug;39(5):809-22. doi: 10.1177/0192623311410442. Epub 2011 Jun 15.

  PMID: 21677315 BACKGROUND

• Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

  PMID: 22256804 BACKGROUND

• Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

  PMID: 20179705 BACKGROUND

• Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005 May;10(5):345-56. doi: 10.1634/theoncologist.10-5-345.

  PMID: 15851793 BACKGROUND

• Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005 Apr 15;174(8):5047-56. doi: 10.4049/jimmunol.174.8.5047.

  PMID: 15814736 BACKGROUND

• Nowak JA, Polak L, Pasolli HA, Fuchs E. Hair follicle stem cells are specified and function in early skin morphogenesis. Cell Stem Cell. 2008 Jul 3;3(1):33-43. doi: 10.1016/j.stem.2008.05.009.

  PMID: 18593557 BACKGROUND

• Mittmann N, Seung SJ. Rash rates with egfr inhibitors: meta-analysis. Curr Oncol. 2011 Apr;18(2):e54-63. doi: 10.3747/co.v18i2.605.

  PMID: 21505590 BACKGROUND

• Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov. 2021 Sep;11(9):2158-2167. doi: 10.1158/2159-8290.CD-20-1847. Epub 2021 Apr 28.

  PMID: 33910927 BACKGROUND

• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006 Oct;6(10):803-12. doi: 10.1038/nrc1970.

  PMID: 16990857 BACKGROUND

• Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

  PMID: 20130576 BACKGROUND

• Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999 Aug;6(8):559-68. doi: 10.1016/s1074-5521(99)80088-x.

  PMID: 10421767 BACKGROUND

• Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, Krystofinski P, Azhdam A, Lee J, Comin-Anduix B, Cochran AJ, Lo RS, Segura T, Scumpia PO, Ribas A. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One. 2021 Jun 23;16(6):e0252597. doi: 10.1371/journal.pone.0252597. eCollection 2021.

  PMID: 34161353 BACKGROUND

• Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348.

  PMID: 27476449 BACKGROUND

• Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 2010 Aug;9(8):2399-410. doi: 10.1158/1535-7163.MCT-10-0181. Epub 2010 Jul 27.

  PMID: 20663930 BACKGROUND

• Balmain A, Ramsden M, Bowden GT, Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature. 1984 Feb 16-22;307(5952):658-60. doi: 10.1038/307658a0.

  PMID: 6694757 BACKGROUND

Study Officials

• Antoni Ribas, M.D., PhD

  University of California, Los Angeles

  STUDY DIRECTOR

• William Zhang, MD

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

• Amanda Truong, MD, PhD

  University of California, Los Angeles

  STUDY CHAIR

• Jeremy C Davis, MD

  University of California, Los Angeles

  STUDY CHAIR

Central Study Contacts

Ignacio Baselga, PhD

CONTACT

3102063548; ibaselga@mednet.ucla.edu

Cynthia R Gonzalez

CONTACT

cynthiargonzalez@mednet.ucla.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of medicine, surgery, and molecular and medical pharmacology at UCLA

Study Record Dates

• First Submitted: March 5, 2026
• First Posted: March 11, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): February 1, 2027
• Last Updated: May 29, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)